JP7081865B2 - サポシンｃ薬学的組成物および癌を治療する方法 - Google Patents

サポシンｃ薬学的組成物および癌を治療する方法 Download PDF

Info

Publication number
JP7081865B2
JP7081865B2 JP2021500778A JP2021500778A JP7081865B2 JP 7081865 B2 JP7081865 B2 JP 7081865B2 JP 2021500778 A JP2021500778 A JP 2021500778A JP 2021500778 A JP2021500778 A JP 2021500778A JP 7081865 B2 JP7081865 B2 JP 7081865B2
Authority
JP
Japan
Prior art keywords
composition
lipids
concentration
phosphatidylserine
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021500778A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021518443A (ja
JP2021518443A5 (https=
Inventor
エレン ケイ． モンソン
シャオチェン ウェイ
レイ タキギク
サード チャールズ エイ． クルーズ
ジョセフ ダブリュ． ワイズ
Original Assignee
ベキシオン ファーマシューティカルズ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ベキシオン ファーマシューティカルズ インコーポレイテッド filed Critical ベキシオン ファーマシューティカルズ インコーポレイテッド
Publication of JP2021518443A publication Critical patent/JP2021518443A/ja
Publication of JP2021518443A5 publication Critical patent/JP2021518443A5/ja
Priority to JP2022082176A priority Critical patent/JP7313091B2/ja
Application granted granted Critical
Publication of JP7081865B2 publication Critical patent/JP7081865B2/ja
Priority to JP2023109939A priority patent/JP2023118847A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1273—Polymersomes; Liposomes with polymerisable or polymerised bilayer-forming substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/40—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving amylase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2334/00—O-linked chromogens for determinations of hydrolase enzymes, e.g. glycosidases, phosphatases, esterases
    • C12Q2334/20—Coumarin derivatives
    • C12Q2334/22—4-Methylumbelliferyl, i.e. beta-methylumbelliferone, 4MU
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/924—Hydrolases (3) acting on glycosyl compounds (3.2)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
JP2021500778A 2018-03-23 2018-11-02 サポシンｃ薬学的組成物および癌を治療する方法 Active JP7081865B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022082176A JP7313091B2 (ja) 2018-03-23 2022-05-19 サポシンｃ薬学的組成物および癌を治療する方法
JP2023109939A JP2023118847A (ja) 2018-03-23 2023-07-04 サポシンｃ薬学的組成物および癌を治療する方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862647058P 2018-03-23 2018-03-23
US62/647,058 2018-03-23
US201862678668P 2018-05-31 2018-05-31
US62/678,668 2018-05-31
PCT/US2018/059016 WO2019182650A1 (en) 2018-03-23 2018-11-02 Saposin c pharmaceutical compositions and methods of treating cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022082176A Division JP7313091B2 (ja) 2018-03-23 2022-05-19 サポシンｃ薬学的組成物および癌を治療する方法

Publications (3)

Publication Number Publication Date
JP2021518443A JP2021518443A (ja) 2021-08-02
JP2021518443A5 JP2021518443A5 (https=) 2022-03-14
JP7081865B2 true JP7081865B2 (ja) 2022-06-07

Family

ID=64664378

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2021500778A Active JP7081865B2 (ja) 2018-03-23 2018-11-02 サポシンｃ薬学的組成物および癌を治療する方法
JP2022082176A Active JP7313091B2 (ja) 2018-03-23 2022-05-19 サポシンｃ薬学的組成物および癌を治療する方法
JP2023109939A Pending JP2023118847A (ja) 2018-03-23 2023-07-04 サポシンｃ薬学的組成物および癌を治療する方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022082176A Active JP7313091B2 (ja) 2018-03-23 2022-05-19 サポシンｃ薬学的組成物および癌を治療する方法
JP2023109939A Pending JP2023118847A (ja) 2018-03-23 2023-07-04 サポシンｃ薬学的組成物および癌を治療する方法

Country Status (16)

Country Link
US (3) US10682411B2 (https=)
EP (2) EP3768246B1 (https=)
JP (3) JP7081865B2 (https=)
KR (2) KR102370952B1 (https=)
CN (2) CN111902133B (https=)
AU (1) AU2018414543B2 (https=)
BR (1) BR112020018334A2 (https=)
CA (1) CA3094928A1 (https=)
ES (1) ES2895180T3 (https=)
IL (1) IL277313B (https=)
MX (1) MX2020009829A (https=)
PL (1) PL3768246T3 (https=)
PT (1) PT3768246T (https=)
RU (1) RU2767199C1 (https=)
SG (1) SG11202007884UA (https=)
WO (1) WO2019182650A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111902133B (zh) * 2018-03-23 2022-04-15 百祥制药公司 皂化蛋白c药物组合物和治疗癌症的方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007127439A2 (en) 2006-04-28 2007-11-08 Children's Hospital Medical Center Compositions comprising fusogenic proteins or polypeptides derived from prosaposin for application in transmembrane drug delivery systems
CN102614125A (zh) 2011-02-01 2012-08-01 常州长吉生物技术开发有限公司 SapC-磷脂纳米囊泡冻干制剂、其制备方法及用途
WO2014078522A1 (en) 2012-11-14 2014-05-22 Ohio State Innovation Foundation Materials and methods useful for treating glioblastoma

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4162282A (en) 1976-04-22 1979-07-24 Coulter Electronics, Inc. Method for producing uniform particles
US4310505A (en) 1979-11-08 1982-01-12 California Institute Of Technology Lipid vesicles bearing carbohydrate surfaces as lymphatic directed vehicles for therapeutic and diagnostic substances
US4533254A (en) 1981-04-17 1985-08-06 Biotechnology Development Corporation Apparatus for forming emulsions
US4728575A (en) 1984-04-27 1988-03-01 Vestar, Inc. Contrast agents for NMR imaging
US4921706A (en) 1984-11-20 1990-05-01 Massachusetts Institute Of Technology Unilamellar lipid vesicles and method for their formation
US4857319A (en) * 1985-01-11 1989-08-15 The Regents Of The University Of California Method for preserving liposomes
US4737323A (en) 1986-02-13 1988-04-12 Liposome Technology, Inc. Liposome extrusion method
IL79559A0 (en) 1986-07-29 1986-10-31 Univ Ramot Contrast agents for nmr medical imaging
US4728578A (en) 1986-08-13 1988-03-01 The Lubrizol Corporation Compositions containing basic metal salts and/or non-Newtonian colloidal disperse systems and vinyl aromatic containing polymers
US5205290A (en) 1991-04-05 1993-04-27 Unger Evan C Low density microspheres and their use as contrast agents for computed tomography
US6271196B1 (en) * 1996-03-05 2001-08-07 Regents Of The University Of Ca Methods of alleviating neuropathic pain using prosaposin-derived peptides
US6872406B2 (en) 2000-02-11 2005-03-29 Children's Hospital Research Foundation Fusogenic properties of saposin C and related proteins and polypeptides for application to transmembrane drug delivery systems
CN100366286C (zh) * 2003-04-28 2008-02-06 常州南云科技有限公司 Saposin C-DOPS:一种抗癌新药
US7834147B2 (en) 2003-04-28 2010-11-16 Childrens Hospital Medical Center Saposin C-DOPS: a novel anti-tumor agent
CN101437485A (zh) 2006-05-09 2009-05-20 高露洁-棕榄公司 口腔护理方案
JP5253402B2 (ja) 2006-10-20 2013-07-31 チルドレンズ ホスピタル メディカル センター 自発的に形成する楕円体の単層リン脂質小胞
CN101209251A (zh) 2006-12-28 2008-07-02 中国科学院理化技术研究所 含有紫杉醇或多烯紫杉醇的弹性纳米囊泡制剂及其制备方法
WO2009049421A1 (en) * 2007-10-18 2009-04-23 The Hospital For Sick Children Compositions and methods for enhancing enzyme activity in gaucher, gm1-gangliosidosis/morquio b disease, and parkinson's disease
WO2010053489A1 (en) * 2008-11-07 2010-05-14 Children's Hospital Medical Center Fusogenic properties of saposin c and related proteins and peptides for application to transmembrane drug delivery systems
US7794969B1 (en) 2009-07-09 2010-09-14 Joule Unlimited, Inc. Methods and compositions for the recombinant biosynthesis of n-alkanes
US20130247924A1 (en) 2012-03-23 2013-09-26 Mark Scatterday Electronic cigarette having a flexible and soft configuration
CN104684546A (zh) * 2012-06-07 2015-06-03 哈佛大学校长及研究员协会 用于药物靶向的纳米疗法
US10760112B2 (en) * 2014-12-18 2020-09-01 Shire Human Genetic Therapies, Inc. Enzymatic activity assays for glucocerebrosidase
US9802942B2 (en) * 2015-07-01 2017-10-31 Northwestern University Substituted 4-methyl-pyrrolo[1,2-A]pyrimidine-8-carboxamide compounds and uses thereof for modulating glucocerebrosidase activity
AU2017361541A1 (en) 2016-11-21 2019-07-11 Bexion Pharmaceuticals, Inc. A combination therapy including SapC-DOPS for the treatment of pancreatic cancer
CN111902133B (zh) * 2018-03-23 2022-04-15 百祥制药公司 皂化蛋白c药物组合物和治疗癌症的方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007127439A2 (en) 2006-04-28 2007-11-08 Children's Hospital Medical Center Compositions comprising fusogenic proteins or polypeptides derived from prosaposin for application in transmembrane drug delivery systems
CN102614125A (zh) 2011-02-01 2012-08-01 常州长吉生物技术开发有限公司 SapC-磷脂纳米囊泡冻干制剂、其制备方法及用途
WO2014078522A1 (en) 2012-11-14 2014-05-22 Ohio State Innovation Foundation Materials and methods useful for treating glioblastoma

Also Published As

Publication number Publication date
CN111902133A (zh) 2020-11-06
IL277313B (en) 2021-05-31
US11590227B2 (en) 2023-02-28
SG11202007884UA (en) 2020-09-29
IL277313A (en) 2020-10-29
US12194099B2 (en) 2025-01-14
US20190290764A1 (en) 2019-09-26
KR102370952B1 (ko) 2022-03-07
JP2021518443A (ja) 2021-08-02
EP3768246B1 (en) 2021-08-25
KR102483046B1 (ko) 2022-12-29
KR20220034916A (ko) 2022-03-18
AU2018414543A1 (en) 2020-11-19
US20200384112A1 (en) 2020-12-10
JP2023118847A (ja) 2023-08-25
WO2019182650A1 (en) 2019-09-26
EP3768246A1 (en) 2021-01-27
ES2895180T3 (es) 2022-02-17
CN114642720A (zh) 2022-06-21
CA3094928A1 (en) 2019-09-26
US20230226188A1 (en) 2023-07-20
BR112020018334A2 (pt) 2021-02-17
AU2018414543B2 (en) 2024-10-03
RU2767199C1 (ru) 2022-03-16
JP7313091B2 (ja) 2023-07-24
CN111902133B (zh) 2022-04-15
EP4005562A1 (en) 2022-06-01
US10682411B2 (en) 2020-06-16
PL3768246T3 (pl) 2022-01-03
KR20200136003A (ko) 2020-12-04
PT3768246T (pt) 2021-09-07
MX2020009829A (es) 2021-01-08
JP2022110121A (ja) 2022-07-28

Similar Documents

Publication Publication Date Title
JP7009559B2 (ja) リポタンパク質複合体ならびにその製造および使用
CN105396122B (zh) 重建高密度脂蛋白制剂及其生产方法
US8349794B2 (en) Reconstitution medium for protein and peptide formulations
JP7313091B2 (ja) サポシンｃ薬学的組成物および癌を治療する方法
AU2020311050B2 (en) Stable formulations of recombinant proteins
IT202000013042A1 (it) Sistema liposomiale con killer tnf-apoptosis induced ligand (killertrail), pro-apoptotico-direzionante.
JP2018535952A (ja) 医薬用コロイド粒子
HK40075391A (en) Saposin c pharmaceutical compositions and methods of treating cancer
HK40036949A (en) Saposin c pharmaceutical compositions and methods of treating cancer
HK40036949B (en) Saposin c pharmaceutical compositions and methods of treating cancer
JP2017531659A (ja) Ｐｅｇ化リポソームおよび血液凝固因子の製剤処方
US20250177479A1 (en) Depsipeptide-based amphiphilic buliding block to inhibit protein-protein interactions, nanostructure comprised thereof and uses thereof
WO2022222945A1 (zh) 一种包含抗体融合蛋白的药物组合物及其用途
KR20230008759A (ko) Il-2 융합 폴리펩티드 조성물 및 그의 제조 및 사용 방법

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200925

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210129

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20211005

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20211005

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211209

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220304

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20220304

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220421

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220519

R150 Certificate of patent or registration of utility model

Ref document number: 7081865

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250